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Background: The inhaled corticosteroid, fluticasone propionate, and the long-acting b2-adren-
ergic agonist, formoterol fumarate, are both highly effective treatments for bronchial asthma.
This study (NCT00393952/EudraCT number: 2006-005989-39) compared the efficacy and safety
of fluticasone/formoterol combination therapy (flutiform; 250/10 mg) administered twice
daily (b.i.d.) via a single aerosol inhaler, with the individual components (fluticasone 250 mg
b.i.d.; formoterol 10 mg b.i.d.), in adult and adolescent patients with moderate-to-severe
asthma.
Methods: This was a 12-week, double-blind, randomised, parallel-group, multicentre, place-
bocontrolled phase 3 study. The co-primary efficacy endpoints were: i) the mean change in
the forced expiratory volume in the first second (FEV1) from morning pre-dose at baseline to
pre-dose at week 12 (fluticasone/formoterol 250/10 mg vs. formoterol), ii) the mean change
in FEV1 from morning pre-dose at baseline to 2 h post-dose at week 12 (fluticasone/formoterol
250/10 mg vs. fluticasone), and iii) the number of patients who discontinued prematurely due
to lack of treatment efficacy (fluticasone/formoterol 250/10 mg vs. placebo). The secondary
endpoints included measures of lung function, disease control, and asthma symptoms. Safety
was assessed based on adverse events, vital signs, and clinical laboratory evaluations.
Results: Overall, 395 (70.9%) patients completed the study. Fluticasone/formoterol 250/10 mg
b.i.d. was superior to the individual components and placebo for all three co-primary0 312 5050; fax: þ1 310 575 9292.
(J. Corren).
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Efficacy/safety of fluticasone/formoterol therapy 181endpoints and demonstrated numerically greater improvements for multiple secondary
efficacy analyses. Fluticasone/formoterol combination therapy had a good safety profile over
the 12 weeks.
Conclusion: Fluticasone/formoterol combination therapy will provide clinicians with an effica-
cious alternative treatment option for patients with moderate-to-severe asthma.
ª 2012 Published by Elsevier Ltd.Introduction
Asthma is a chronic inflammatory airway disorder, associated
with variable airflow limitation as a result of exaggerated
bronchoconstriction, airway hyperresponsiveness andmucus
hypersecretion.1,2 It is estimated to affect at least 300
million people and represents approximately 1% of the total
disease burden worldwide.1,3,4
Inhaled corticosteroids (ICSs) are the first line of therapy
in targeting airway inflammation and hyperresponsiveness
and are the mainstay of therapy for asthma of all severity
levels.1,5e7 In patients who present with moderate, persis-
tent asthma, orwhohaveuncontrolled symptomsdespite the
use of a low to moderate dose of ICS, current guidelines
recommend the addition of an inhaled long-acting b2-
adrenergic agonist (LABA)which alleviates asthma symptoms
for at least 12 h1,8 The addition of a LABA to ICS therapy has
been shown to be clinically more effective than doubling the
dose of ICS administered, with greater improvements in lung
function, and reductions in exacerbations and days with
poorly controlled asthma.1,6,8e12 The benefits of ICS/LABA
therapy are supportedby in vitro research suggesting that, at
the molecular level, the two compounds exert a synergistic
mechanism of action when suppressing airway inflammation
and alleviating bronchoconstriction, respectively.13e16
This has led to the development of ICS/LABA single inhaler
combination therapy.17e22 The likelihood of patient adher-
ence to a treatment regimen is increased with the use of
asthma therapy administered via a single inhaler,whichmay,
as a consequence, lead to improved asthma control in terms
of better lung function and a reduction in asthma exacer-
bations.23,24 However, despite the commercial availability of
efficacious combination therapies, asthma remains poorly
controlled for a significant proportion of patients.4,25e28
Fluticasone propionate (fluticasone) is a potent ICS with
a well-established efficacy and safety profile,18,29e33 while
formoterol fumarate (formoterol) is a LABA with a rapid
onset of action of between 1 and 3 min, and sustained,
dose-dependent bronchodilatory effects.32e36
The present study was undertaken to evaluate the effi-
cacy and tolerability of a new asthma therapy combining
fluticasone and formoterol, administered twice daily (b.i.d.)
via a single aerosol inhaler (fluticasone/formoterol 250/
10 mg), in adult and adolescent patients with moderate-to-
severe asthma.
Methods
This was a 12-week, randomised, double-blind, placebo-
and active-controlled, stratified, parallel-group study,
performed at 78 centres in North America and Europe (July2006 to April 2008; EudraCT number: 2006-005989-39; US
NCT number: NCT00393952). The study was conducted in
accordance with the International Conference on Harmo-
nisation guidelines on Good Clinical Practice and the ethical
principles of the Declaration of Helsinki. The protocol was
reviewed and approved by the Institutional Review Boards
or Independent Ethics Committees of the respective
participating centres and all patients, or the parents or
guardians of those less than 18 years of age, provided
written informed consent before enrolment.Patients
Male and female patients, aged 12 years and over, with
a history of symptomatic asthma for at least 12 months prior
to screening, as defined by the National Asthma Education
and Prevention Program,37 were eligible for inclusion in this
study. Eligible patients had a documented use of ICS therapy
for at least 4 weeks prior to screening at a dose of no more
than 500 mg/day inhaled fluticasone (or equivalent ICS dose).
At both screening and baseline (week 0), all patients were
required to have a forced expiratory volume in the first
second (FEV1) between 40% and 80% (inclusive) of predicted
normal values following appropriate withholding of bron-
chodilatormedication; treatmentwith any LABA therapywas
discontinued at least 24 h, and with any short-acting b2-
agonist at least 6 h, prior to the first pulmonary function test.
Patientswere also required todemonstrate FEV1 reversibility
(14.5% increase in FEV1 15e30 min following albuterol/
salbutamol aerosol inhalation)within 12months prior to or at
the screening visit. During any 7 consecutive days of the
14  3 day run-in period, patients had to use 2 or more
inhalations per day of rescue medication (albuterol/salbu-
tamol) for at least 3 days and to either have at least 3 days
with asthma symptoms or one night with sleep disturbance
due to asthma in order to be eligible for randomisation. All
patients were required to demonstrate satisfactory aerosol
technique and correct use of the telephone diary system.
Patients were excluded from the study if they had
a history of life-threatening asthma, hospitalisation or prior
intubation for asthma either during the previous 12 months
or during the run-in period. If patients had used systemic
corticosteroids within 3 months, omalizumab within 6
months or a leukotriene receptor antagonist within a week
prior to screening, they were also excluded. If patients had
significant, non-reversible pulmonary disease (e.g. chronic
obstructive pulmonary disease, cystic fibrosis or bronchiec-
tasis), or experienced respiratory tract infections within the
4 weeks prior to screening or during the run-in, a significant
medical illness, had a smoking history of at least 10 pack-
years or within the previous 12months, or hypersensitivity to
182 J. Corren et al.any study medication, they were excluded from the study.
Patients receiving b-blockers, tricyclic antidepressants,
monoamine oxidase inhibitors, quinidine-type antiarrhyth-
mics, or drugs known to inhibit CYP3A4,within theweekprior
to the screening visit were also ineligible for participation.
Treatments
During the open-label run-in period, patients received flu-
ticasone as asthma maintenance therapy at a dose that was
dependent on individual steroid usage prior to screening:
patients who were taking less than 250 mg fluticasone
(or equivalent ICS dose) per day received 100 mg/day
fluticasone (1 actuation 50 mg fluticasone b.i.d.), and
patients requiring more than 250 mg fluticasone (or equiv-
alent ICS dose) per day received 200 mg/day fluticasone (2
actuations 50 mg fluticasone b.i.d.). All study participants
were permitted the use of rescue albuterol/salbutamol, as
needed, for worsening asthma symptoms.
At the end of the run-in period, patients who met the
randomisation criteria, as described above, were assigned
equally to one of the five, blinded treatment arms (Fig. 1).
Every morning and evening throughout the 12-week study
period, each patient self-administered two actuations from
two aerosol devices, for a total of 8 inhalations per day,
according to their allocated treatment arm: 2 actuations of
125/5 mg b.i.d. fluticasone/formoterol and placebo b.i.d.
(both hydrofluoroalkane [HFA] pMDI, SkyePharma), 2 actu-
ations of fluticasone 125 mg b.i.d. (Flovent HFA pMDI,
GlaxoSmithKline) and placebo b.i.d., 2 actuations of for-
moterol 5 mg b.i.d. (HFA pMDI, SkyePharma, Switzerland)
and placebo b.i.d., 2 actuations of fluticasone/formoterol
50/5 mg b.i.d. and placebo b.i.d., or 2 actuations b.i.d.
from two devices both containing placebo. With the
exception of salbutamol/albuterol rescue medication, all
other asthma medications were prohibited during the
study. Study medications were administered via a pMDI
without the use of a spacer. Patients received instructions
and training on their use during the screening visit, and
inhaler technique and dosing procedures were reviewed at
each study visit. Patients were instructed to take morning
and evening doses as evenly spaced as possible, and were
required to leave a 1-min interval between inhalations and
wash their mouth thoroughly after dosing.Figure 1 StuPatients were randomised according to minimisation with
biasedcoinassignment38and treatment groupswerebalanced
on baseline FEV1 % predicted (40%e60% or >60%e80%), study
site, and the subgroup of patients aged 12e18 years. An
Interactive Voice Response System was used for subject
enrolment and treatment allocation, and blinding was main-
tained throughout the study with the use of dummy placebo
inhalers. All investigators, personnel at the study site, and
representatives involved in monitoring, data management
and any other aspect of the trial, including sponsor personnel,
were blinded throughout the study. Adherence to study
medicationwas assessedbasedonthenumberofactuations of
study and rescuemedication recorded by patients throughout
the run-in and treatment periods. The baseline visit was at
week 0 and followed the run-in. Patients were scheduled to
visit the sites for clinical assessments at weeks 2, 4, 8, and 12
(or final visit for early discontinuations), and a safety follow-
up was carried out by telephone 2 weeks following the last
dose of study medication.
Efficacy assessments
The primary objective of the study was to evaluate the
efficacy of fluticasone/formoterol 250/10 mg b.i.d. combi-
nation therapy compared with fluticasone, formoterol, and
placebo using three co-primary endpoints. The efficacy
of the fluticasone component of fluticasone/formoterol
250/10 mg b.i.d. was evaluated by comparing the combina-
tion product with formoterol alone using the mean change in
FEV1 from pre-dose at baseline (week 0) to pre-dose at week
12. The efficacy of the formoterol component of flutica-
sone/formoterol 250/10 mg b.i.d. was assessed by comparing
the combination product with fluticasone alone using the
mean change in FEV1 from pre-dose at baseline to 2 h post-
dose at week 12. The efficacy of the combination product
compared with placebo was demonstrated by the time to
discontinuation due to lack of efficacy, defined as either
a severe exacerbation or the loss of asthma control, with the
two classifications combined for the analysis. A severe
exacerbation was defined as the deterioration in the
patient’s asthma requiring additional therapy such as
a systemic steroid, a visit to the emergency room or hospi-
talisation due to asthma. The loss of asthma control was
defined as a decrease in pre-dose FEV1 of more than 20%dy design.
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ratory flow rate (PEFR) of more than 25% from baseline on
more than 3 of the 7 days before a study visit; excessive use
(12 actuations per day) of rescue medication on more than
3 of the 7 days before a study visit, and nocturnal awaken-
ings due to asthma that required rescue medication use on
more than 2 of 7 days before a study visit.
Secondary efficacy endpoints includedboth data obtained
from the telephone diaries and from additional pulmonary
function tests. Patient recorded data included morning and
evening PEFR; rescue medication use; asthma symptom
scores (from 0 for no symptoms to 5 for where asthma was so
severe that the patient was unable to go to work or school or
carry out normal daily activities); symptom-free days
(defined as days with asthma symptom score of 0); rescue
medication-free days (defined as days with no use of rescue
medication); asthma control days (defined as days with an
asthma score of 0, a sleep disturbance score of 0, and no use
of rescue medication); type and frequency of asthma exac-
erbations (defined as mild to moderate if the pre-dose
morning PEFR measurement was more than 30% below base-
line values, or if the patient experienced awakening at night
due to asthma for at least 2 consecutivedays, or if theyhad toFigure 2 Patientuse additional rescuemedication of more than 3 inhalations/
day comparedwith baseline on at least 2 consecutive days; or
as severe exacerbations, as defined above); sleep distur-
bance scores (from 0 where patient slept through the night
and experienced no asthma to 4 where the patient could not
sleep at all due to asthma), and awakening-free nights
(defined as nights with a sleep disturbance score of 0).
Additional pulmonary function tests included changes
from baseline to each post-dose time point in FEV1, PEFR,
FEV1 % predicted normal, and forced vital capacity (FVC). In
addition, the 12-h serial FEV1 area under the curve (AUC)
was to be assessed in a subset population, whereby serial
pulmonary function tests were also performed post-dose at
6, 8, 10, and 12 h following the morning dose at weeks 0, 2,
and 12. The FEV1 AUC analyses were carried out to deter-
mine the efficacy of the 250/10 mg combination product
compared with each of the monocomponents and placebo.
FEV1 was measured
39 at baseline and at weeks 2, 4, 8,
and 12, and the predicted FEV1 values from Polgar and
Promadhat40 and Crapo et al41 were used for adolescents
(12e17 years) and adults (18 years), respectively. In
addition to age, height, and sex, the predicted spirometry
values were also adjusted for race.flow diagram.
Table 1 Demographic and asthma characteristics, safety population.
Characteristic
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d
N Z 110
Fluticasone
250 mg b.i.d.
N Z 113
Formoterol
10 mg b.i.d.
N Z 111
Placebo
b.i.d.
N Z 109
Fluticasone/Formoterol
100/10 mg b.i.d.
N Z 113
Overall
N Z 556
Gender, n (%)
Female 64 (58.2) 63 (55.8) 67 (60.4) 71 (65.1) 67 (59.3) 332 (59.7)
Male 46 (41.8) 50 (44.2) 44 (39.6) 38 (34.9) 46 (40.7) 224 (40.3)
Ethnic origin, n (%)
White/Caucasian 92 (83.6) 89 (78.8) 91 (82.0) 94 (86.2) 99 (87.6) 465 (83.6)
Black 13 (11.8) 12 (10.6) 13 (11.7) 8 (7.3) 6 (5.3) 52 (9.4)
Asian 0 0 0 1 (0.9) 1 (0.9) 2 (0.4)
Hispanic 5 (4.5) 10 (8.8) 7 (6.3) 5 (4.6) 6 (5.3) 33 (5.9)
Other 0 2 (1.8) 0 1 (0.9) 1 (0.9) 4 (0.7)
Age, years
Mean (SD) 44.8 (15.66) 41.9 (15.17) 42.8 (15.51) 42.6 (15.48) 43.4 (14.22) 43.1 (15.19)
Median 46.5 44.0 45.0 43.0 45.0 45.0
MineMax 12e80 12e76 12e82 12e79 12e72 12e82
Age categories, n (%)
12e17 y 8 (7.3) 9 (8.0) 9 (8.1) 6 (5.5) 9 (8.0) 41 (7.4)
 18 y 102 (92.7) 104 (92.0) 102 (91.9) 103 (94.5) 104 (92.0) 515 (92.6)
Baseline FEV1 % predicted, n (%)
40%e60% 36 (32.7) 37 (32.7) 37 (33.3) 36 (33.0) 37 (32.7) 183 (32.9)
>60%e80% 74 (67.3) 76 (67.3) 74 (66.7) 73 (67.0) 76 (67.3) 373 (67.1)
Duration of asthmaa, years
Mean (SD) 20.25 (14.606) 19.93 (14.960) 19.08 (14.468) 21.12 (15.323) 21.72 (15.080) 20.42 (14.866)
Median 16.95 14.70 15.00 18.90 19.10 16.75
MineMax 1.1e63.3 1.2e63.3 1.1e64.1 1.2e69.3 2.0e61.9 1.1e69.3
FEV1 % predicted
b at baselinec
Mean (SD) 64.9 (10.45) 65.7 (18.36) 65.3 (11.36) 64.1 (10.78) 64.3 (11.58) 64.9 (12.85)
Median 66.0 67.0 67.0 65.0 65.0 66.0
MineMax 41e89 39e225d 40e102 41e82 40e105 39e225
FEV1at baseline
c, L
Mean (SD) 2.082 (0.5512) 2.140 (0.5850) 2.136 (0.6246) 2.068 (0.5222) 2.098 (0.5871) 2.105 (0.5740)
Median 2.025 2.080 2.070 2.060 2.010 2.055
MineMax 1.05e3.53 0.96e3.91 0.91e4.10 1.09e3.34 0.91e3.94 0.91e4.10
Reversibility at
screening, % N Z 109 N Z 113 N Z 109 N Z 111 N Z 109 N Z 551
Mean (SD) 24.67 (11.949) 27.95 (14.556) 26.98 (12.353) 26.99 (14.749) 25.72 (12.658) 26.46 (13.297)
Median 20.00 22.70 22.50 21.80 21.60 21.70
MineMax 14.6e78.4 14.6e109.6 14.5e74.3 10.1e91.2 14.6e92.7 10.1e109.6
a Duration of asthma calculated as (date of screening visit from demographics CRF - asthma diagnosis date)/365.25 and rounded to 1 decimal place.
b Based on standardised predicted FEV1 values.
c Baseline was the last available value prior to dosing at the baseline/week 0 visit.
d Patient was a 36-year-old Caucasian female who weighed 64 kg with a height of 104 cm.
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the treatment efficacy in terms of lung function, disease
control, and asthma symptoms, for fluticasone/formoterol
combination therapy at the 100/10 mg b.i.d. dose level.
Safety assessments
Safety was assessed throughout the study based on adverse
events, vital signs, a 12-lead electrocardiogram (ECG), and
clinical laboratory testing.
Statistical analyses and sample size calculation
Efficacy analyses were carried out on the full analysis set
(FAS), which included all randomised patients who had at
least one dose of study medication, a pre-dose FEV1
measurement at baseline, a pre-dose FEV1 measurement
post-baseline, and a 2-h post-dose FEV1 measurement post-
baseline. The per-protocol (PP) population comprised all
patients in the FAS who did not have a major protocol
violation; the safety population included all patients who
received at least one inhalation of study medication after
randomisation, and the AUC population included all
patients who participated in the subset of 12-h post-dose
serial pulmonary function tests and who had a minimum
of four measured FEV1 values.
An analysis of covariance (ANCOVA) determined the
change in FEV1 from pre-dose at baseline (week 0) to pre-
dose and to 2 h post-dose at week 12, with treatment
group (fluticasone/formoterol 250/10 mg b.i.d., fluticasone,
formoterol, and placebo), study centre, and baseline FEV1 %
predicted category (40%e60% or >60%e80%) as factors, and
baseline FEV1 as a continuous covariate. A stratified log-
rank test was performed for the analysis of discontinua-
tions due to lack of efficacy, adjusting for baseline FEV1 %
predicted category. Only the two relevant treatment groups
being compared were included in the analyses.Table 2 Mean change in FEV1 (L) from pre-dose at baseline to p
carried forward imputation, full analysis set.
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 108
Baseline FEV1 (L) Mean (SD) 2.085 (0.5509)
Change in FEV1 from pre-dose at baseline to pre-dose at week 12
LS Mean (SE)a 0.184 (0.043)
Difference from fluticasone/formoterol 250/10 mg b.i.d.: contrib
LS Mean (SE)a
95% CIa
p-valuea
Change in FEV1 from pre-dose at baseline to 2 h post-dose at we
LS Mean (SE)a 0.357 (0.040)
Difference from fluticasone/formoterol 250/10 mg b.i.d.: contrib
LS Mean (SE)a
95% CIa
p-valuea
SDZ standard deviation; LSZ least squares; SEZ standard error; NA
a LS mean, SE, CI, and p-value are from ANCOVA with factors for disp
fluticasone, formoterol, and placebo), site, and baseline FEV1 % predicStatistical analyses of the following secondary efficacy
endpoints were carried out using an ANCOVA as for the
co-primary endpoints: the difference between fluticasone/
formoterol 250/10mgb.i.d. and the comparators (fluticasone,
formoterol, and placebo) with respect to change from pre-
dose at baseline to bothpre-dose, and 2 h post-dose, atweeks
2, 4, 8, and 12 for FEV1, PEFR, FEV1 % predicted normal and
FVC, with the relevant baseline value as the covariate;
morning and evening PEFR; asthma symptom scores; sleep
disturbance scores, and rescue medication use. Differences
between treatment groups, for the change from baseline to
week 12, for symptom-free days, rescue medication-free
days, asthma control days, and awakening-free nights were
assessed using van Elteren’s method for combining Wilcoxon
rank sum test results from independent strata, with baseline
FEV1 % predicted category and study site as the main effects.
Differences between the treatment groups for the proportion
of patients who reported at least one treatment-emergent
asthma exacerbation were assessed using logistic regression
with effects for the four treatment groups (fluticasone/for-
moterol 250/10 mg b.i.d., fluticasone, formoterol, and
placebo), and baseline FEV1 % predicted category.
If all three co-primary endpoints were statistically signif-
icant then the secondary endpoints were evaluated in
a confirmatory manner using a sequential gatekeeper
approach.42 The order for the treatment comparisons was as
follows: i) fluticasone/formoterol 250/10 mg b.i.d. combina-
tion product vs. placebo, and ii) fluticasone/formoterol 250/
10 mg b.i.d. combination product vs. fluticasone alone and vs.
formoterol alone. The first four secondary endpoints were
analysed in the following order, based on the mean change
from baseline to week 12: morning PEFR, evening PEFR,
rescuemedication use, and asthma symptom scores. Thefirst
comparative test was combination product vs. placebo for
each of these four endpoints. If each of these tests returned
statistically significant results (statistical analyses werere-dose and to 2 h post-dose at week 12 using last observation
Fluticasone
250 mg b.i.d.
N Z 109
Formoterol
10 mg b.i.d.
N Z 110
Placebo
b.i.d.
N Z 105
2.134 (0.5848) 2.143 (0.6237) 2.066 (0.5154)
0.106 (0.041) 0.004 (0.041) 0.011 (0.043)
ution of fluticasone component
NA 0.189 (0.056) NA
NA 0.079, 0.298 NA
NA < 0.001 NA
ek 12
0.211 (0.039) 0.292 (0.039) 0.123 (0.040)
ution of formoterol component
0.146 (0.053) NA NA
0.042, 0.250 NA NA
0.006 NA NA
Z not applicable; CIZ confidence interval; b.i.d.Z twice daily.
layed treatment groups (fluticasone/formoterol 250/10 mg b.i.d.,
ted category, with baseline FEV1 value as a continuous covariate.
Figure 3 Mean change in FEV1 (L) from pre-dose at baseline to pre-dose at weeks 2, 4, 8, and 12: the contribution from the
fluticasone component of fluticasone component of fluticasone/formoterol 250/10 mg b.i.d. combination therapy, full analysis set
using last observation carried forward imputation.
186 J. Corren et al.two-sided and significance wasmeasured at the 0.05a level),
then comparative testing could be carried out for combina-
tion therapy vs. fluticasone and vs. formoterol for each of the
four endpoints. If one of the tests was not significant at the
0.05a level, for example evening PEFR for combinationFigure 4 Mean change in FEV1 (L) from pre-dose at baseline to 2
formoterol component of fluticasone component of fluticasone/for
using last observation carried forward imputation.product vs. fluticasone alone, then the subsequent test (i.e.
evening PEFR for combination product vs. formoterol alone)
could be evaluated at the 0.025a level, however all formal
testing of the remaining secondary endpointswas suspended.
Similarly, if statistical significancewas not reached for eitherh post-dose at weeks 2, 4, 8, and 12: the contribution from the
moterol 250/10 mg b.i.d. combination therapy, full analysis set
Figure 5 Time to discontinuations due to lack of efficacy, full analysis set.
Efficacy/safety of fluticasone/formoterol therapy 187comparator, for example for either fluticasone or formoterol
alone, then all of the remaining confirmatory sequential
testing was also formally suspended.
If the sequential gatekeeperapproach for eachof the three
comparative tests was statistically significant for each of the
four secondary endpoints, then confirmatory sequential
testing of the remaining endpoints was carried out in theTable 3 Mean change in morning and evening PEFR (L/Min) fro
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 108
AM PEFR (L/min)a n Z 103
Baselineb Mean (SD) 348.3 (84.13)
Change from baseline to week 12
LS Mean (SE)
28.367 (5.256)
Difference from fluticasone/formoterol 250/10 mg b.i.d.
LS Mean (SE)
95% CI
p-value
PM PEFR (L/min)a n Z 103
Baselineb Mean (SD) 358.4 (85.56)
Change from baseline to week 12
LS Mean (SE)
23.847 (4.902)
Difference from fluticasone/formoterol 250/10 mg b.i.d.
LS Mean (SE)
95% CI
p-value
AM Z morning; PM Z evening; PEFR Z peak expiratory flow rate; SD
CIZ confidence interval; b.i.d.Z twice daily; NZ number of patient
a LS mean, SE, CI, and p-value are from ANCOVA with factors for d
category, with Baseline PEFR value as a continuous covariate.
b Baseline was the average of the highest of the 3 daily measures c
c Statistically significant difference versus fluticasone/formoterol 2following order, using the samemethodology andcomparative
sequence as described above, for the mean change from
baseline to week 12: the percentage of symptom-free days,
percentage of rescue medication-free days, percentage of
asthma control days, the proportion of patients with
treatment-emergent asthma exacerbations, sleep distur-
bance scores, and percentage of awakening-free nights.m baseline to week 12, full analysis set.
Placebo
b.i.d.
N Z 105
Fluticasone
250 mg b.i.d.
N Z 109
Formoterol
10 mg b.i.d.
N Z 110
n Z 104 n Z 104 n Z 109
343.9 (87.71) 344.9 (96.01) 338.9 (88.12)
12.567 (5.103) 12.472 (5.052) 0.713 (4.934)
40.934 (6.830) 15.894 (6.915) 27.654 (6.757)
27.501, 54.367 2.295, 29.494 14.365, 40.942
<0.001c 0.022c <0.001c
n Z 104 n Z 105 n Z 108
351.7 (86.78) 352.4 (93.65) 348.1 (87.87)
13.770 (4.758) 10.646 (4.691) 4.426 (4.610)
37.618 (6.370) 13.201 (6.419) 28.273 (6.315)
25.090, 50.145 0.576, 25.827 15.853, 40.694
<0.001c 0.040c <0.001c
Z standard deviation; LS Z least squares; SE Z standard error;
s in treatment group; nZ number of patients with data available.
isplayed treatment groups, site, and baseline FEV1 % predicted
ollected in the last 7 days prior to the first dose of study drug.
50/10 mg b.i.d. based on sequential gatekeeper approach.
188 J. Corren et al.There were no inferential statistical tests carried out
to compare fluticasone/formoterol 250/10 mg b.i.d. and
100/10 mg b.i.d. treatment arms. Missing observed data for
both the primary and secondary efficacy analyses were
managed using last observation carried forward (LOCF)
imputation. All tests were two-sided and p-values below
0.05 were considered statistically significant.
For analysis of the co-primary efficacy endpoints,
a sample size of 108 patients in each of the five treatment
arms (540 patients in total) would have 85% power to detect
a significant difference between two treatment groups
using a two-sided t-test with a Z 0.05, assuming a differ-
ence in FEV1 of 0.2 L (considered as a clinically significant
change) and common Standard Deviation (SD) of 0.45, and
taking into account an approximate dropout rate of 15%.
Results
Overall, 1219 patients were screened and, of these, 557
patients, including 41 (7.4%) adolescents, were randomisedTable 4 Overview of secondary efficacy variables. Disease c
symptom-free days, and awakening-free nights: mean change fro
Characteristic
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 108
Asthma control days (%) n Z 103
Baselinea mean (SD) 12.9 (20.48)
Week 12 mean (SD) 53.8 (42.69)
Change to week 12
Mean (SD) 40.9 (40.98)
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
p-value
Rescue medication-free days (%) n Z 103
Baselinea mean (SD) 19.8 (25.15)
Week 12 mean (SD) 60.4 (39.70)
Change to week 12
Mean (SD) 40.6 (42.11)
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
p-value
Symptom-free days (%) n Z 103
Baselinea mean (SD) 24.3 (25.82)
Week 12 mean (SD) 61.1 (41.40)
Change to week 12
Mean (SD) 36.8 (36.66)
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
p-value
Awakening-free nights (%) n Z 103
Baselinea mean (SD) 62.4 (35.36)
Week 12 mean (SD) 82.5 (30.27)
Change to week 12
Mean (SD) 20.1 (40.74)
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
p-value
N Z number of patients in treatment group, n Z number of patients
a Baseline was the 7-day average calculated on the last 7 days prio
b Analysis method was Cochran-Mantel-Haenszel using van Elteren
independent strata, with baseline FEV1 % predicted category and site
c p  0.050 versus fluticasone/formoterol 250/10 mg b.i.d. but notto treatment, 381 in the United States and 176 in Europe. In
total, 395 (70.9%) patients completed the study and 162
(29.1%) discontinued (Fig. 2). Treatment groups were well
matched in terms of patient demographics, baseline char-
acteristics, medical history and pulmonary function (Tables
1 and 2), with little difference between the treatment
groups in terms of lung function reversibility: the median
FEV1 % predicted at baseline ranged from 20.00 to 22.70
(Table 1). Approximately 40% of patients received ICS/LABA
combination therapy prior to study entry. The FAS
comprised 543 patients, the PP population comprised 466
patients, and the safety population comprised 556 patients
(excluding one patient who was randomised but not dosed).
Mean compliance rate in the safety population across all
treatment groups was 86.8%.
Primary efficacy endpoints
Treatment with fluticasone/formoterol 250/10 mg b.i.d.
combination therapy demonstrated superior efficacy for allontrol: asthma control days, rescue medication-free days,
m baseline to week 12, full analysis set.
Placebo
b.i.d.
N Z 105
Fluticasone
250 mg b.i.d.
N Z 109
Formoterol
10 mg b.i.d.
N Z 110
n Z 101 n Z 102 n Z 106
11.2 (19.09) 9.8 (18.72) 10.9 (22.02)
27.3 (35.25) 45.2 (41.47) 39.7 (39.18)
16.1 (37.08) 35.4 (38.90) 28.7 (43.20)
0.001c 0.027c 0.032c
n Z 104 n Z 106 n Z 109
17.6 (22.61) 15.2 (21.40) 21.9 (27.06)
34.9 (35.65) 50.6 (40.63) 47.2 (39.94)
17.3 (37.27) 35.5 (36.80) 25.3 (43.01)
0.009c 0.042c 0.013c
n Z 104 n Z 105 n Z 108
24.3 (27.59) 20.3 (25.91) 24.5 (31.34)
38.6 (38.76) 53.9 (40.81) 51.8 (40.83)
14.3 (39.98) 33.6 (37.14) 27.4 (41.71)
0.007c 0.342 0.140
n Z 104 n Z 104 n Z 109
60.7 (31.59) 59.6 (35.34) 61.9 (34.77)
70.4 (34.15) 82.0 (29.94) 80.9 (28.20)
9.7 (38.95) 22.4 (38.91) 19.0 (37.69)
0.209 0.810 0.240
with data available, SD Z standard deviation.
r to the first dose of study drug.
’s method for combining Wilcoxon rank sum test results from
as the strata for the analysis.
statistically significant per sequential gatekeeping approach.
Efficacy/safety of fluticasone/formoterol therapy 189three co-primary endpoints (Table 2; Figs. 3e5). The
contribution of the fluticasone component from the
combination therapy, as analysed by the mean change in
FEV1 from pre-dose at baseline to pre-dose at week 12,
demonstrated statistically significant improvements for
fluticasone/formoterol compared with formoterol alone (LS
mean treatment differenceZ 0.189 L; p < 0.001; Table 2).
Similarly, the contribution of the formoterol component of
the combination therapy, as analysed by the mean change
in FEV1 from pre-dose at baseline to 2 h post-dose at week
12, demonstrated statistically significant improvements for
fluticasone/formoterol compared with fluticasone alone
(LS mean treatment differenceZ 0.146 L; pZ 0.006; Table
2). The improvements in pre-dose FEV1 (Fig. 3) and 2-h post-
dose FEV1 (Fig. 4) throughout the study period for treatment
with fluticasone/formoterol 250/10 mg, fluticasone, for-
moterol, and placebo are illustrated by the pulmonary
function tests carried out at Weeks 2, 4, 8, and 12.
The fluticasone/formoterol 250/10 mg b.i.d. combina-
tion therapy was also superior to placebo with respect to
the time to discontinuation due to lack of efficacy (due
either to asthma exacerbation or to loss of asthma control;
log-rank p < 0.001; Fig. 5). Fewer patients administered
the 250/10 mg b.i.d. combination product discontinuedTable 5 Number of patients with treatment-emergent asthma
Characteristic
Treatment group
Fluticasone/Formot
250/10 mg b.i.d.
N Z 108
Any asthma exacerbation (%) 26 (24.1)
Odds ratioa
95% CI
p-valuea
Any mild to moderate asthma
exacerbationb n (%)
24 (22.2)
Odds ratioa
95% CI
p-valuea,c
Any severe asthma exacerbationd n (%) 4 (3.7)
Odds ratioa
95% CI
p-valuea,c
Time to first asthma exacerbation (weeks)
Median 1.55
p-valuee,c
Time to first severe asthma exacerbation (weeks)
Median 4.30
p-valuee,c
NZ number of patients in treatment group; nZ number of patients w
a Odds ratio, 95% CI and p-value for fluticasone/formoterol 250/10
factors for treatment group and baseline FEV1 % predicted category.
b Defined as pre-dose morning PEFR >30% below baseline, or awak
additional rescue albuterol/salbutamol pMDI >3 inhalations per day w
c These endpoints were tertiary and p-values were not controlled f
d Defined as deterioration in asthma requiring additional therapy, i
asthma.
e Log-rank test was used to compare fluticasone/formoterol 25
KaplaneMeier method.
f p  0.050 versus fluticasone/formoterol 250/10 mg b.i.d. but notprematurely due to lack of efficacy (11 patients, 10.2%)
compared with each of the three comparator groups
(fluticasone: 14 patients (12.8%); formoterol: 23 patients
(20.9%); placebo: 41 (39.0%); Fig. 2).
Secondary efficacy endpoints
The secondary efficacy endpoints were evaluated according
to improvements in lung function, disease control, and
asthma symptoms from baseline to week 12. These results
supported the superior efficacy of fluticasone/formoterol
250/10 mg b.i.d., with overall numerically greater
improvements for patients administered the combination
product compared with those receiving the individual
components or placebo. Many of the comparisons met the
criteria for statistically significant differences between the
combination and each of the comparators as analysed
according to the gatekeeping approach.
Lung function was assessed on the mean change in
morning and evening PEFR values from baseline to week 12,
and both assessments demonstrated statistically signifi-
cantly greater improvements for patients receiving the
combination product compared with those administered
fluticasone alone, formoterol alone, and placebo (Table 3).exacerbations, full analysis set.
erol Placebo
b.i.d.
N Z 105
Fluticasone
250 mg b.i.d.
N Z 109
Formoterol
10 mg b.i.d.
N Z 110
54 (51.4) 30 (27.5) 48 (43.6)
3.40 1.19 2.48
1.88, 6.12 0.64, 2.20 1.38, 4.45
<0.001f 0.030f 0.055
38 (36.2) 26 (23.9) 35 (31.8)
1.99 1.09 1.64
1.09, 3.66 0.58, 2.06 0.89, 3.02
0.040 0.229 0.329
24 (22.9) 5 (4.6) 16 (14.5)
7.84 1.24 4.48
2.60, 23.60 0.32, 4.75 1.44, 13.92
<0.001 0.054 0.042
2.00 1.95 2.95
<0.001 0.575 0.002
3.50 4.10 3.00
<0.001 0.740 0.004
ith data available; CIZ confidence interval; b.i.d.Z twice daily.
mg b.i.d. versus comparator from logistic regression model with
ening at night due to asthma for 2 consecutive days, or use of
ith respect to baseline for 2 consecutive days.
or multiple testing.
.e. systemic steroid, or emergency visit or hospitalisation due to
0/10 mg b.i.d. versus comparator for survival analyses using
statistically significant per sequential gatekeeping approach.
190 J. Corren et al.Disease control was evaluated using asthma control days,
rescuemedication-freedays, symptom-freedays, awakening-
free nights (Table 4) and asthma exacerbations (Table 5).
Fluticasone/formoterol 250/10 mg b.i.d. combination therapy
demonstrated numerically greater improvements for each
measure of disease control, with the exception of awakening-
free nights, however, none of the treatment differences
between the combination product and the individual
components or placebo was considered statistically signifi-
cant based on the sequential gatekeeper approach.
Evaluations of asthma symptoms were assessed accord-
ing to inhalations/day of rescue medication, asthma
symptom scores and sleep disturbance scores obtained
from patient diaries. Fluticasone/formoterol 250/10 mg
b.i.d. combination therapy demonstrated numerically
greater improvements compared to the individual compo-
nents and placebo, with the exception of sleep disturbance
scores versus fluticasone (Table 6). There were statistically
significant treatment differences in measures of rescue
medication use (inhalations/day) for the combination
product compared with formoterol and placebo, and inTable 6 Overview of secondary efficacy variables. Asthma sym
symptom scores, and sleep disturbance scores: mean change from
Characteristic
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 108
P
b
N
Rescue medication use
(inhalations/day)
n Z 103 n
Baselinea mean (SD) 2.8 (1.63) 2
Change to week 12
Mean (SE)b 1.188 (0.217) 0
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
LS Mean (SE) 
95% CI 
p-value <
Asthma symptom scores n Z 103 n
Baselinea mean (SD) 1.0 (0.48) 1
Change to week 12
Mean (SE)b 0.496 (0.069) 
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
LS Mean (SE) 
95% CI 
p-value <
Sleep disturbance scores n Z 103 n
Baselinea mean (SD) 0.4 (0.46) 0
Change to week 12
LS Mean (SE)b 0.193 (0.043) 
Difference from fluticasone/formoterol 250/10 mg b.i.d.b
LS Mean (SE) 
95% CI 
p-value 0
NZ number of patients in treatment group; nZ number of patients w
SD Z standard deviation; SE Z standard error; b.i.d. Z twice daily.
a Baseline was the 7-day average calculated in the last 7 days prior
b LS mean, SE, CI and p-value are from ANCOVA with factors for tre
baseline value as a continuous covariate.
c p  0.050 versus fluticasone/formoterol 250/10 mg b.i.d. and stat
d p  0.050 versus fluticasone/formoterol 250/10 mg b.i.d. but notasthma symptom scores compared with placebo, based on
the sequential gatekeeping approach (Table 6).
Table 7 shows the 12-h serial FEV1 AUC evaluation, based
on a subgroup of 282 patients. Summary statistics show that
the mean 12-h FEV1 AUC was numerically greater for the
combination product than fluticasone at weeks 0, 2, and 12.
The mean changes from pre-dose at baseline over 12 h at
week 0 (post first dose) and at week 12 are presented in
Fig. 6a and b, respectively.
The results for the fluticasone/formoterol 100/10 mg
b.i.d. treatment group were comparable with those of the
250/10 mg b.i.d. dose treatment groups for the two spiro-
metric co-primary endpoints, the secondary endpoints, and
the number of asthma exacerbations reported by patients.
Safety and tolerability
Overall, 556 randomised patients were included in the safety
population and had a mean duration of study drug exposure
of 10.2 weeks. The overview of adverse events reported by
patients in each of the treatment arms, including theptoms: use of rescue medication (inhalations/day), asthma
baseline to week 12, full analysis set.
lacebo
.i.d.
Z 105
Fluticasone
250 mg b.i.d.
N Z 109
Formoterol
10 mg b.i.d.
N Z 110
Z 104 n Z 106 n Z 109
.9 (1.70) 3.1 (1.81) 2.8 (1.94)
.107 (0.211) 1.122 (0.207) 0.484 (0.203)
1.295 (0.282) 0.066 (0.285) 0.704 (0.279)
1.850, 0.740 0.626, 0.494 1.253, 0.155
0.001c 0.817 0.012c
Z 104 n Z 105 n Z 108
.1 (0.66) 1.2 (0.58) 1.1 (0.70)
0.081 (0.067) 0.406 (0.066) 0.267 (0.065)
0.414 (0.090) 0.090 (0.091) 0.229 (0.089)
0.592, 0.237 0.269, 0.089 0.405, 0.053
0.001c 0.324 0.011d
Z 104 n Z 104 n Z 109
.5 (0.46) 0.5 (0.51) 0.5 (0.50)
0.043 (0.042) 0.216 (0.042) 0.163 (0.041)
0.150 (0.056) 0.023 (0.057) 0.030 (0.056)
0.261, 0.039 0.090, 0.135 0.140, 0.080
.008d 0.690 0.594
ith data available; CIZ confidence interval; LSZ least squares;
to the first dose of study drug.
atment group, site, and baseline FEV1 % predicted category, with
istically significant per sequential gatekeeping approach.
statistically significant per sequential gatekeeping approach.
Table 7 12-h serial FEV1 AUC (L-hour), AUC population using observed data.
FEV1 AUC
a
Treatment group
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 73
Fluticasone
250 mg b.i.d.
N Z 71
Formoterol
10 mg b.i.d.
N Z 71
Placebo
b.i.d.
N Z 67
Week 0 (After first dose), n 73 71 71 67
Mean (SD) 0.295 (0.2566) 0.097 (0.2156) 0.303 (0.2554) 0.145 (0.2713)
Median 0.266 0.070 0.295 0.075
MineMax 0.44, 1.05 0.36, 0.65 0.29, 1.19 0.41, 1.03
Week 2, n 69 68 67 61
Mean (SD) 0.316 (0.2821) 0.206 (0.3062) 0.214 (0.3061) 0.064 (0.3144)
Median 0.302 0.144 0.194 0.006
MineMax 0.26, 1,21 0.36, 1.30 0.87, 1.17 0.69, 1.01
Week 12, n 65 65 54 48
Mean (SD) 0.311 (0.2815) 0.203 (0.3355) 0.229 (0.3428) 0.093 (0.3814)
Median 0.281 0.146 0.206 0.022
MineMax 0.35, 1.09 0.68, 1.19 0.61, 1.23 0.51, 1.15
NZ number of patients in treatment group; nZ number of patients with data available; AUCZ area under the curve; FEV1Z forced
expiratory volume in the first second; Max Z maximum; Min Z minimum; SD Z standard deviation.
a At each visit, AUC calculated only in case of at least 4 measured post-dose FEV1 values. AUC calculated using the linear trapezoidal
rule: the area between 2 consecutive time points was calculated as [(time 2 e time 1) * (change at time 1 þ change at time 2)]/2. The
areas were summed and time weighted for the 12 h.
Efficacy/safety of fluticasone/formoterol therapy 191number of events considered by the Investigator to be at
least possibly related to study medication, is summarised in
Table 8. Adverse events were predominantly mild or
moderate in severity. Severe adverse events were reported
by 59 patients (Table 9). The only severe adverse event
noted in more than one patient was asthma, as reported by 3
(2.7%) patients in the fluticasone/formoterol 250/10 mg
b.i.d. group; 5 (4.4%) patients in the fluticasone/formoterol
100/10 mg b.i.d. group; 6 (5.3%) in the fluticasone group; 16
(14.4%) in the formoterol group, and 21 (19.3%) patients in
the placebo group. The most frequently reported adverse
events were asthma, nasopharyngitis, and upper respiratory
tract infection (Table 9), adverse events, which are all
typical of this type of treatment.43 Study medication-
related oral candidiasis was only observed in two patients
(1.8%) in the fluticasone treatment group, and dysphonia for
one patient administered fluticasone/formoterol 100/10 mg
b.i.d.. Serious adverse events were experienced by 6
patients (1 administered fluticasone/formoterol 250/10 mg
b.i.d.; 2 administered fluticasone/formoterol 100/10 mg
b.i.d.; 2 in the fluticasone group, and one in the formoterol
group), none of which were considered by the Investigator to
be study medication related. No deaths were reported.
Overall, there were no significant differences in adverse
events between treatment groups.
There were no clinically relevant changes or group
differences for laboratory values, vital signs, or ECG
parameters.Discussion
This study compared the efficacy and safety of fluticasone/
formoterol 250/10 mg b.i.d. with the individual components
administered alone, and placebo, over a 12 week study
period. The study population consisted of adolescents and
adults with moderate-to-severe asthma (FEV1 40e80% ofpredicted normal values; FEV1 reversibility 14.5%) who
required inhaled corticosteroid therapy prior to screening.
The three co-primary efficacy endpoints showed that flu-
ticasone/formoterol 250/10 mg b.i.d. was superior compared
with each of the individual ICS and LABA components
administered separately, and placebo. The clinically impor-
tant and statistically significant difference between flutica-
sone/formoterol 250/10 mg b.i.d. and formoterol for the
change in FEV1 from pre-dose at baseline to pre-dose at week
12 showed the contribution of the fluticasone component of
the combination. The difference between fluticasone/for-
moterol 250/10 mg b.i.d. and fluticasone for mean change in
FEV1 from pre-dose at baseline to 2 h post-dose at week 12
demonstrated the contribution from the formoterol compo-
nent. Fluticasone/formoterol 250/10 mg b.i.d. was also
shown to be superior to placebo for time to discontinuation
due to lack of efficacy. Increases in 12-h serial FEV1were seen
with formoterol and the fluticasone/formoterol 250/10 mg
b.i.d. combination following the first treatment dose, as ex-
pectedwith a LABA,whereas fluticasone, whichwould not be
expected to have had an effect at this time, showed similar
changes in serial FEV1 to those with placebo. Importantly,
after 12 weeks of treatment, the effects of fluticasone on 12-
h serial FEV1 were greater than those of placebo, although
they were smaller than those of fluticasone/formoterol.
The improvements in FEV1 were experienced by
patients shortly after treatment initiation (week 2) with
fluticasone/formoterol 250/10 mg b.i.d. and were sustained
over the 12-week treatment period. This was supported by
the patient-recorded PEFR data, which showed statistically
significant differences in the changes from baseline to week
12 between the 250/10 mg b.i.d. combination and the
comparator groups. The mean 12-h FEV1 AUC of fluticasone/
formoterol 250/10 mg b.i.d. was also numerically greater
than that for fluticasone throughout the treatment period.
These results are consistent with findings from studies
comparing other single-inhaler ICS/LABA combinations with
Figure 6 Mean change from pre-dose at baseline in 12-h serial FEV1 (L) after (a) the first dose at week 0 and (b) 12 weeks of
treatment, 12-h serial FEV1 analysis set using observed data.
192 J. Corren et al.their individual component therapies.44e46 Fluticasone/sal-
meterol and budesonide/formoterol combinations have
each shown significantly greater improvements in FEV1 and
PEFR, and significantly longer time to withdrawal because ofworsening asthma, compared with individual monotherapies
and placebo in 12-week studies in patients who were
previously receiving inhaled corticosteroids therapy.18,47,48
Similarly, beclometasone/formoterol has demonstrated
Table 8 Overview of patients with treatment-emergent adverse events, safety population.
Number (%) of patients
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 110
Fluticasone
250 mg b.i.d.
N Z 113
Formoterol
10 mg b.i.d.
N Z 111
Fluticasone/Formoterol
100/10 mg b.i.d.
N Z 113
Placebo
b.i.d.
N Z 109
Any adverse event 34 (30.9) 48 (42.5) 39 (35.1) 42 (37.2) 52 (47.7)
Any serious adverse event 1 (0.9) 2 (1.8) 1 (0.9) 2 (1.8) 0 (0.0)
Any severe adverse event 4 (3.6) 9 (8.0) 17 (15.3) 8 (7.1) 21 (19.3)
Any adverse event leading to study
discontinuationa
4 (3.6) 9 (8.0) 17 (15.3) 5 (4.4) 26 (23.9)
Any adverse event with probable or
possible relationship to study drug
7 (6.4) 11 (9.7) 12 (10.8) 3 (2.7) 20 (18.3)
Any adverse event leading to death 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
a Three of the 61 patients (1 fluticasone/formoterol 250/10 mg b.i.d., 1 fluticasone, and 1 placebo) had adverse event reported as the
primary reason for early discontinuation. Two (1 fluticasone, 1 placebo) of the 61 patients had adverse event reported as primary reason
for early discontinuation from study. An additional 55 patients (3 fluticasone/formoterol 250/10 mg b.i.d., 5 fluticasone/formoterol
100/10 mg b.i.d., 7 fluticasone, 16 formoterol, and 24 placebo) had lack of efficacy reported as the primary reason for early discon-
tinuation from the study, and had adverse events reported with “study therapy permanently stopped” as an action taken. In addition,
the adverse event for 1 formoterol patient was reported on Day 84 (Week 12 Visit) and thus, the patinet was considered to have
completed the study.
Efficacy/safety of fluticasone/formoterol therapy 193superiority to beclometasone dipropionate alone for
measures of lung function, including morning PEFR and
FEV1, in patients with moderate-to-severe asthma over 24
weeks’ treatment.22
The multiple secondary endpoints used to measure
disease control and asthma symptoms, evaluated using the
gatekeeper methodology, showed clinically important
improvements throughout the course of the study forTable 9 Number (%) of patients with treatment-emergent adv
group, safety population.
System organ class preferred
term
Number (%) of patients
Fluticasone/Formoterol
250/10 mg b.i.d.
N Z 110
Flutic
250 mg
N Z 1
Any event 34 (30.9) 48 (42
Infections and infestations 15 (13.6) 20 (17
Nasopharyngitis 5 (4.5) 6 (5.
Upper respiratory tract
infection
3 (2.7) 4 (3.
Sinusitis 1 (0.9) 2 (1.
Urinary tract infection 1 (0.9) 1 (0.
Respiratory, thoracic and
mediastinal disorders
6 (5.5) 13 (11
Asthmaa 4 (3.6) 6 (5.
Cough 2 (1.8) 1 (0.
Nervous system disorders 8 (7.3) 4 (3.
Headache 5 (4.5) 3 (2.
Gastrointestinal disorders 6 (5.5) 5 (4.
Nausea 0 (0.0) 3 (2.
Note: Adverse events were coded using MedDRA version 9.0. At eac
overall), each patient was counted only once. Percentages are based
group.
a An exacerbation of asthma was considered as an adverse event if
additional medication was required (e.g. systemic glucocorticosteroidpatients receiving 250/10 mg b.i.d. combination therapy.
Overall, these results supported the superior efficacy of
fluticasone/formoterol 250/10 mg b.i.d. compared to the
each of the individual components and placebo.
Asthma control is clinically perhaps the most relevant
endpoint to patients, and although it was a non-validated
measure, the definition of asthma control used in this study
(asthma score of 0, sleep disturbance score of 0, and no useerse events reported for >2.0% of patients in any treatment
asone
b.i.d.
13
Formoterol
10 mg b.i.d.
N Z 111
Fluticasone/Formoterol
100/10 mg b.i.d.
N Z 113
Placebo
b.i.d.
N Z 109
.5) 39 (35.1) 42 (37.2) 52 (47.7)
.7) 17 (15.3) 23 (20.4) 19 (17.4)
3) 3 (2.7) 8 (7.1) 3 (2.8)
5) 6 (5.4) 2 (1.8) 3 (2.8)
8) 1 (0.9) 1 (0.9) 3 (2.8)
9) 3 (2.7) 2 (1.8) 0 (0.0)
.5) 22 (19.8) 12 (10.6) 28 (25.7)
3) 18 (16.2) 6 (5.3) 25 (22.9)
9) 1 (0.9) 3 (2.7) 1 (0.9)
5) 4 (3.6) 3 (2.7) 4 (3.7)
7) 3 (2.7) 1 (0.9) 3 (2.8)
4) 1 (0.9) 3 (2.7) 3 (2.8)
7) 0 (0.0) 0 (0.0) 0 (0.0)
h level of summation (preferred term, system organ class and
on the number of patients in the population for each treatment
it did not resolve with the study drug, including albuterol, and
s).
194 J. Corren et al.of rescue medication) is highly suggestive of a meaningful
change in asthma status. Patient recorded asthma symptom
scores and the proportion of asthma control days were
numerically greatest for fluticasone/formoterol 250/10 mg
b.i.d. compared to the monotherapies and placebo. In
addition, the 250/10 mg b.i.d. combination demonstrated
numerically greater effects compared to the three
comparator groups for each of the constituent components
of asthma control. This study was not powered for the
analysis of asthma exacerbations, which would require
much larger patient numbers and longer study timescales.
However, patients in the 250/10 mg b.i.d. combination
therapy group reported fewer exacerbations, mild-to-
moderate as well as severe, compared to the other groups.
The improvements in measures of asthma control seen
with the fluticasone/formoterol combination are also in
line with findings for other ICS/LABA combination studies.
These have also shown greater improvements in asthma
exacerbations and measures of asthma control, such as
symptom scores, rescue medication use, symptom-free
days and awakening-free nights free, compared with their
individual components.18,22,47,48
As well as the primary and secondary endpoints
comparing fluticasone/formoterol 250/10 mg b.i.d with
each of the individual components and placebo, a low dose
(100/10 mg b.i.d.) combination therapy arm was included in
this study. The results for the two fluticasone/formoterol
treatment arms were comparable. This was as expected for
fluticasone-containing treatments administered at these
dose levels.31 The flat dose-response for all currently
approved classes of inhaled monotherapies in asthma is
well recognised. Typically, wide dose separation is required
to demonstrate differences in efficacy, i.e. for spirometry
results, across a dose range for both ICSs and b2-
agonists43,49,50 and would involve doses separated by
a greater dose multiple than used here.
In conclusion, fluticasone/formoterol combination
therapy demonstrated a good safety profile, similar to that
of the individual components, and was well-tolerated
during the 12-week treatment period. The results of this
study therefore successfully demonstrated the benefits of
the new fluticasone/formoterol 250/10 mg b.i.d. therapy
providing superior efficacy compared to its individual
components and placebo for the management of moderate
to severe asthma. For such adolescent and adult patients,
who require ICS/LABA therapy, fluticasone/formoterol will
present an efficacious alternative treatment option.Disclaimer
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